To examine the effect of treatment with an inactivated, gp120-depleted, HIV-1 immunogen (Remune) in 30 Thai subjects infected with HIV-1 subtype E.
Introduction
New effective drug 'cocktails' that target viral replication have become part of the standard of care for many HIV-1-infected individuals in the United States and Europe. Factors such as adherence to complicated drug regimens, resistance, tolerability, and immune reconstitution remain practical public health issues for patients taking combination antiviral drug therapy. Unfortunately, access to highly active antiretroviral therapy has been limited to the industrialized countries. Thus, in developing countries, access to the newer antiviral drug combinations is limited and currently no alternative effective treatment modalities exist. Furthermore, current epidemiological studies suggest an abrupt increase in AIDS cases worldwide [1] . Estimates of future rates suggest that Asia may, in fact, surpass Africa in the incidence of AIDS cases by the year 2000 [1] . Thailand still has a high incidence of HIV infection despite its implementation of many public health policy initiatives to limit the spread of disease [2, 3] . Nevertheless, there is a growing need to study alternative treatments because antiviral drug combinations are not readily available. We examined the effect of an HIV-1-specific immune-based therapy (Remune; Immune Response Corp., Carlsbad, California, USA) as an approach to treating HIV infection. Remune is composed of an HIV-1 isolate (HZ 321 ) from serum collected from a patient in former Zaïre in 1976, which has been recently sequenced and classified as having clade A envelope and clade G gag, and grown in the Hut78 T-cell line [4] .
Previous clinical studies of HIV-1-seropositive subjects in the United States treated with a gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (IFA; HIV-1 immunogen, Remune) revealed an augmentation of HIV-1-specific immune responses as measured by lymphocyte proliferation [5] , antibody [5, 6] delayed-type hypersensitivity [6] , and production of β-chemokines [7, 8] . In previous clinical studies conducted prior to the advent of commercial plasma RNA assays, a slower rise in the number of HIV-1 proviral DNA copies in peripheral blood mononuclear cells (PBMC) and a stabilization in the CD4 cell percentage was observed in a treatment group compared with adjuvant control subjects [5] .
In this study, 30 HIV-1-infected Thai subjects received treatment with an inactivated gp120-depleted HIV-1 virus in IFA (Remune) and were followed for 60 weeks in an open-label treatment study. Subjects were not taking antiviral drugs during treatment, and 29 subjects had been infected with HIV-1 subtype E. The initial safety and immunogenicity during the first 4 months of the trial has been previously reported [9] . We now report on a longer follow-up of the same subjects.
Methods

Study design and demographics
Approval was obtained from the National AIDS Committee, the Technical Subcommittee on AIDS Vaccines, and the Ethical Committee (Ministry of Public Health, Thailand). The study enrolled 30 subjects from a single center, Ramathibodi Hospital, Bangkok, Thailand, with CD4 cell counts of at least 300 × 10 6 /l. Treatment was administered as open label therapy with an intramuscular injection of Remune. Injections were administered on the first day of study (day 1) and then at 4, 8, 12, 24, 36, 48 and 60 weeks after the initial injection.
Treatment
Remune consisted of inactivated gp120-depleted HIV-1 formulated in IFA for intramuscular injection into the triceps muscle. Inactivated HIV-1 antigen was obtained by concentration and purification by anion exchange chromatography from filtered supernatant fluid or a chronically infected (HZ 321 ) Hut78 cell line [10] .
CD marker cell phenotyping
CD4 and CD8 cell percentages were obtained using a validated protocol performed on fresh PBMC. Immunophenotyping was performed at the BioService Unit (BIOTEC Center, National Science and Technology Development Agency, Thailand), using a FACvantage flow cytometer (Becton Dickinson, San Diego, California, USA). Prior to each operation, the performance of the instrument was carefully checked according to the manufacturer's recommendation, which included optimal alignment, spectral compensation, and electronic standardization. Normal cells and calibration beads (CaliBrite, Becton Dickinson) were used to minimize autofluorescence and to perform spectral compensation, respectively. Heparinized blood samples were collected from HIV-infected subjects, transported to the laboratory, and immunophenotyping was carried out within 2 h of blood collection. Immunophenotyping was performed strictly according to the manufacturer's protocol using Simultest reagent (Becton Dickinson), a monoclonal antibody reagent for two-color enumeration of CD4/CD8 cells. Light-scattering gating was performed to identify the lymphocyte subset. The gated cells were further defined by the binding of the two monochrome-tagged monoclonal antibodies.
Safety measurements
After obtaining written informed consent, enrolled subjects were interviewed to obtain details of medical history, including previous HIV-related diagnoses, and physical examinations were performed. Subjects were monitored during the trial for adverse events at each visit. In addition, body weight and appetite of the enrolled subjects were monitored at each visit. Safety laboratory investigations included liver (e.g., aspartate aminotransferase, alanine aminotransferase) and renal function (e.g., blood urea nitrogen, creatinine) tests. Enzyme levels in the kidney and liver were measured and recorded before the first inoculation then periodically during the study period.
Viral load
Plasma HIV-1 RNA was assayed in blinded samples by Advanced Bioscience Laboratories, Inc. (Kensington, Maryland, USA) using the nucleic acid sequence-based amplification method [11] . The lower limit of detection of this assay was 4000 copies/ml. Samples below the limit of the assay were assigned a value of 4000 copies/ml for the purpose of statistical analysis.
Immunogenicity
The ability of Remune to stimulate HIV-specific immune responses was examined by Western blotting of subject plasma before and after treatment at each study visit. For Western blotting, nitrocellulose strips contain-ing the sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE)-separated HZ 321 antigen were incubated with subject plasma diluted in 10% non-fat milk in 0.1% phosphate-buffered saline (PBS) at a 1 : 50 dilution. Western blot for detection of antibodies to HIV-1 immunogen (Remune) in volunteer plasma was performed at the Immunochemistry Unit (Department of Pathobiology, Faculty of Science, Mahidol University). The inactivated HIV-1 antigen was supplied by The Immune Response Corporation (Carlsbad, California, USA) and purified as described by Prior et al. [12] . Eight per cent PAGE in presence of 4% SDS was used [13, 14] . Ten microliters of inactivated HIV-1 antigen that had been previously diluted to a 1 : 1 ratio in standard 2× sample buffer (Sigma Chemical Co., St Louis, Missouri, USA) were separated by electrophoresis for 2 h 30 min at 40 mA. The separated antigens were then transferred onto the surface of a nitrocellulose membrane by the Western blot method.
Plasma from treated volunteers was diluted at 1 : 50 ratio with 10% (weight/vol) non-fat dry milk (Sanalac; Hunt-Wesson, Fullerton, California, USA) in Trisbuffered saline (pH 7.4) using 0.05 ml plasma in 2.45 ml buffer. The paired plasma samples obtained at baseline and week 60 from each subject were tested retrospectively in one batch for comparison of results. After incubation for 3 h, the strips were washed four times in 0.1% PBS and incubated with goat anti-human horseradish peroxidase-conjugated anti-IgG and developed for visualization of the serological response to HIV antigens. The results were recorded and compared between those obtained in the pre-and post-treatment plasma from each volunteer to see whether there was an increase in the number of reactive HIV-specific bands or a demonstrably greater intensity of the pre-existing bands in week 60 plasma relative to the subject's baseline plasma sample.
Viral subtyping
Viral subtyping was performed by the Department of Microbiology at Siriraj Hospital (Bangkok, Thailand), using a peptide enzyme-limited immunosorbent assay (ELISA) [15] and heteroduplex mobility assay (HMA) [16] . The 14-amino-acid peptides specific for Thai A (env subtype E, TSITIGPGQVFYRT) and Thai B (env subtype B, KSIHLGPGQAWYTT) were used with ELISA for this study. The primers ED3/14 and ED5/12 were used in HMA and their PCR products were compared in 5% polyacrylamide gels. As noted previously, 29 out of 30 subjects had subtype E virus and one subject had subtype B virus [9] .
Statistical analysis
The non-parametric Wilcoxon signed rank test was used to test for significant changes from baseline for the various markers. Spearman rank correlation was used to determine strength and direction of association between markers. All P values are two-tailed. RNA values were natural log-transformed to normalize the data because of the limited range of 12 000 to 200 000 copies/ml.
Results
Baseline demographics for the subjects are shown in Table 1 . Sixteen (53%) of the subjects were women and 14 (47%) were men. The subjects' ages ranged from 19 to 41 years (median, 30 years). Six of the 30 subjects were on antiviral drugs (the most common being zidovudine followed by didanosine) a few months prior to enrollment into the study period but had stopped taking antiviral drugs for 3 months or more before recruitment into the study due to lack of funds. However, discontinuing antiviral drugs was not a requirement for this protocol. The mean CD4 cell count at baseline was 451 × 10 6 /l (range, 220-894 × 10 6 /l) and CD4 cell percentage was 17.1% (range, 10.9-34.4%) in these subjects.
Treatment with Remune was well-tolerated with no serious adverse events noted. Local injection site reactions (i.e., swelling, redness, induration), which resolved within 30 min were the predominant adverse events reported.
Most subjects had an increased intensity of antibody bands and also developed new reactivities to HIV proteins on Western blots ( Table 2 ). The most common new reactivity was to the conserved proteins of the virus. An increase in both the number of bands and intensity were noted in 15 cases. The remaining eight cases demonstrated only an intensity increase mostly due to an already existing optimum number of bands detected by this method. Two cases revealed stable reactivities. Five cases showed decreased intensity of reactive bands with one case showing a loss of antibody to at least one polypeptide and another showing more antibodies but decreased band intensity.
Because HIV-1 is a wasting disease, we examined changes in weight in these subjects. Weight significantly increased from baseline (mean ± SE, 54.9 ± 1.3 kg) to 60 weeks (mean ± SE, 56.0 ± 1.4 kg; P < 0.0001; Fig. 1 ).
We also examined changes in phenotypic markers of CD4 and CD8 cell percentages (Fig. 2 pretreatment baseline [mean ± SE, 8.1 ± 0.2 ln copies/0.1 ml (32 945 ± 12 copies/ml); Fig. 3 ]. Furthermore, plasma RNA weakly inversely correlated with CD4 cell percentage (r = −0.27, P = 0.04).
Discussion
In this group of 30 Thai subjects infected with HIV-1 subtype E and not taking antiviral drug regimens, we have observed a significant increase in CD4 cell count, CD4 and CD8 cell percentages, and body weight after treatment with a gp120-depleted HIV-1 immunogen (Remune). In addition, increased HIV-1-specific immune responses as measured by antibody to the conserved epitopes of the virus such as p17 were observed. Finally, this regimen was well-tolerated and no serious adverse events were observed. The safety profile after treatment with Remune in this trial is consistent with that observed in trials of Remune in the United States [17] . Local transient injection site reactions were observed shortly after immunization in three cases, which resolved within 30 min without treatment. This is a common side-effect of treatment in this study as well as in the US studies. Furthermore, a Phase II trial in Thailand and a Phase III trial in the United States are ongoing and will provide a safety database for thousands of HIV-1-infected subjects treated with Remune.
In a previous study of Remune, healthy, predominantly antiviral-naive HIV-1-seropositive subjects developed increased antibody responses to the conserved HIV-1 protein p24 [18] . Similar HIV-1-specific antibody responses to the more conserved epitopes of the virus have also been observed in other US studies of Remune [refs? ]. In this Thai study, increased and new responses were demonstrated to conserved proteins such as p24, p17 and p15. Interestingly, antibody responses to the more conserved core proteins, but not envelope proteins, have been demonstrated by others to indicate a better prognostic course [19] . In this group of Thai subjects, in contrast to the previous US studies, subjects were predominantly infected with HIV-1 subtype E. Interestingly, in US studies of Remune it has been observed that HIV-1-specific immune responses could be generated to the Asian subtype E antigen as well to the common US clade B virus [20] . Thus, an immunogen composed of the more conserved epitopes of the virus is capable of enhancing immune responses across clades.
Body weight also increased in these subjects. This is consistent with an observation made in an earlier US trial with Remune [21] . Although a modest mean gain of 1.1 kg was noted in the Thai study, weight continues to be highly prognostic for patients with HIV-1 infection and an indicator of overall quality of life [22] .
Recently, agents such as growth hormone have been approved and made available for wasting patients in the United States [23] .
Significant increases in CD4 cell count, CD4 and CD8 cell percentages were noted in this study. CD4 cell count and CD4 cell percentage continues to be a useful prognostic marker of disease progression, despite the rapid emergence of other surrogate markers [24] . CD4 cell count assays have recently been validated by different methods in Thailand [25] . The increases in CD4 cell percentage observed in this study after treatment are also consistent with a previous US trial of Remune [18] . Although a decline in the number of CD4 cells is well-documented and characteristic of HIV-1 infection, virus-specific immune function is not completely conveyed by the number of CD4 lymphocytes [20] . Interestingly, the functional immune response against the virus, as measured as the quantity of lymphocytes proliferating in culture to conserved core HIV antigens (p24), was recently demonstrated to be associated with control of plasma viremia in antiviral-naive subjects [26, 27] . Although not measured in the present study, previous studies of Remune have revealed increased lymphocyte proliferative responses to the highly conserved p24 antigen after treatment [8, 18, 20] .
The increases in CD8 cell percentage observed in this study are intriguing considering the recent interest in CD8 cell-derived HIV-suppressive factors such as the β-chemokines [28] . CD8 cell viral suppressive factors such as the β-chemokines (RANTES, macrophage inflammatory proteins 1α and 1β) have been reported to inhibit viral replication of macrophage-tropic strains of HIV-1 in vitro [28] . High levels of HIV-1 antigeninduced β-chemokine production have been associated with low viral load in antiviral-naive subjects in other studies [29] . Whether the reported increases in CD8 cell percentage observed in this group of Thai subjects represents increased functional responses was not determined in the present study. In previous studies, though, we have observed an increase in HIV-specific CD8 cell production of β-chemokines after treatment with Remune [20, 30] . Studies are now underway to examine chemokine production in Thai subjects treated with Remune.
Finally, viral load in subjects with detectable levels at baseline had a decrease in plasma RNA at week 60 compared with pretreatment values. In the entire group of subjects, viral load did not change, due in part to the fact that half of the subjects had undetectable plasma RNA at baseline and most remained undetectable during the study period. Recent studies have documented on-going viral production that is not quantified by peripheral blood plasma RNA levels [31, 32] . Thus the inducement of HIV-1-specific immune responses may be a useful strategy to potentially suppress viral spread in such subjects. The clinical utility of augmenting HIV-1-specific immune responses against the virus may not be easily quantifiable by plasma RNA in subjects with already undetectable plasma RNA levels, such as those studied here. Nevertheless, the impact of treatment on other measurements of viral load, such as proviral DNA, are being examined in cohorts of subjects receiving Remune.
In summary, in Thai HIV-1-infected subjects, significant increases in HIV-1-specific immune responses, body weight, CD4 cell count, and CD4 and CD8 cell percentages were observed after treatment with Remune. Furthermore, treatment with Remune was well tolerated. Plasma RNA was stable in these subjects and decreased in those subjects with detectable viral load at baseline. These results indicate that HIV-specific immune-based therapeutic approaches to treating HIV-1 infection such as Remune should be further examined in countries with different clades of HIV-1 and where access to antiviral drug therapy is limited. A doubleblind adjuvant controlled study in Thailand is ongoing in order to confirm these preliminary observations.
